Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy

Cancer Gene Therapy

Volumn 7, Issue 5, 2000, Pages 799-805

  Hoshi, Michio ^a   Harada, Asako ^a   Kawase, Takeshi ^a   Uyemura, Keiichi ^a   Yazaki, Takahito ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Gene therapy; Glioma; Herpes simplex virus type 1; Matrix metalloproteinase; Tissue inhibitor of metalloproteinases

Indexed keywords

MATRIX METALLOPROTEINASE; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VIRUS VECTOR;

ARTICLE; BRAIN TUMOR; ENZYME INHIBITION; GENE THERAPY; GLIOMA; GLIOMA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40; SIMPLEXVIRUS;

EID: 0034106261     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700177     Document Type: Article

References (25)

1. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938-943.
2. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995;55:4752-4756.
3. Andersen J, Garber D, Meaney C, Breakefield X. Gene transfer into mammalian central nervous system using herpes simplex vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther. 1992;3:487-499.
4. Dobson A, Margolis TP, Sedarati F, Stevens J, Feldman LT. A latent, nonpathogenic HSV-1-derived vector stably expresses β-galactosidase in mouse neurons. Neuron. 1990; 5:353-360.
5. Fink D, Stenberg L, Weber P, Mata M, Gonis W, Glorioso J. In vivo expression of β-galactosidase in hippocampal neurons by HSV-1-mediated transfer. Hum Gene Ther. 1992;3:11-19.
6. Rutka JT, Matsuzawa K, Hubbard S, et al. Expression of TIMP-1, TIMP-2, 72-and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. Int J Oncol. 1995;6:877-884.
7. Abe T, Mori T, Kohno K, et al. Expression of 72-kDa type IV collagenase and invasion activity of human glioma cells. Clin Exp Metastasis. 1994;12:296-304.
8. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci. 1997;110:2473-2482.
9. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg. 1995;83: 298-307.
10. Nakagawa T, Kubota T, Kabuto M, Fujimoto N, Okada Y. Secretion of matrix metalloproteinase-2 (72-kDa gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix. J Neurooncol. 1996;28:13-24.
11. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed in the surface of invasive tumour cells. Nature. 1994;37:61-65.
12. Rooprai HK, McCormick D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res. 1997; 17:4151-4162.
13. Zhang H, Kelly G, Zerillo C, Jaworski DM, Hockfield S. Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci. 1998;18:2370-2376.
14. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Nagase H. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinases 2 (gelatinase A) activated on the cell surface. J Biol Chem. 1998;38:24360-24367.
15. Lampert K, Machein U, Machein MG, Conca W, Peter HH, Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol. 1998;153:429-437.
16. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg. 1994;81:69-77.
17. Kaplitt M, Peaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW. Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1-defective viral vector. Mol Cell Neurosci. 1991;2:320-330.
18. Γ 92,000 type IV collagenases in human brain tumors. Cancer Res. 1993;53: 2208-2211.
19. Johnson P, Miyanohara A, Levine F, Cahill T, Friedman T. Cytotoxicity of replication-defective mutant of herpes simplex virus type 1. J Virol. 1992;66:2952-2965.
20. Marsden HS, Crombie IK, Subak-Sharpe JH. Control of protein synthesis in herpes virus-infected cells: analysis of the polypeptides induced by wild-type and sixteen temperature-sensitive mutants of HSV strain 17. J Gen Virol. 1976;31:347-372.
21. Davison MJ, Preston VG, McGeoch DJ. Determination of the sequence alternation in the DNA of the herpes simplex virus type 1 temperature-sensitive mutant tsK. J Gen Virol. 1984;65:859-863.
22. DeLuca N, McCarthy A, Schaffer P. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol. 1985:56:558-570.
23. DeLuca N, Schaffer P. Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides. Nucleic Acids Res. 1987;15:4491-4511.
24. Paterson T, Everett R. A prominent serine-rich region in Vmw175, the major transcriptional regulator protein of herpes simplex virus type 1, is not essential for virus growth in tissue culture. J Gen Virol. 1990;71:1775-1783.
25. Herrlinger U, Kramm CM, Aboody-Guterman KS, et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 1998;5:809-819.